Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06095102 · ClinicalTrials.gov registry record · Phase 3
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
A Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
- 20
- Study locations
NCT06095102: Active Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
NCT06095102 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 311 participants, below the 409-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06095102, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Primary Outcome
IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema, scaling, each using 5 point scale. Induration:0=no evidence of plaque elevation, 1=minimal plaque elevation,=0.25 millimeters(mm); 2=mild plaque elevation,=0.5 mm; 3=moderate plaque elevation,=0.75 mm; 4=severe plaque elevation,\>1 mm; Erythema: 0=no evidence of erythema, hyperpigmentation may be present, 1=faint erythema, 2=light red coloration, 3=moderate red coloration, 4=bright red coloration; Scaling:
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-77242113
Study Locations (20)
Illinois
- Arlington Dermatology - Rolling Meadows
- Dundee Dermatology - West Dundee
Indiana
- Dawes Fretzin Clinical Research Group LLC - Indianapolis
- Indiana Clinical Trial Center - Plainfield
Pennsylvania
- Paddington Testing Co, Inc. - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Arizona
- Center for Dermatology and Plastic Surgery - Scottsdale
Arkansas
- Johnson Dermatology - Fort Smith
California
- California Dermatology & Clinical Research Institute - Encinitas
Florida
- Forcare Clinical Research Inc - Tampa
Georgia
- Hamilton Research LLC - Alpharetta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2027-02-17 |
| Phase | Phase 3 |
What the registry record for NCT06095102 still lists
NCT06095102 is an interventional study that assigns participants to a tested intervention. The registered 311 participants enrollment target is mid-sized for trials with a published cap, below the 409-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06095102 names 20 study sites across 17 states, led by Illinois, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06095102 about?
NCT06095102 is a clinical study titled "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)". The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
What is the current status of trial NCT06095102?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2023-10-12. Estimated completion is 2027-02-17.
What conditions does trial NCT06095102 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06095102?
The interventions under investigation include: Placebo (DRUG), JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT06095102?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06095102 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06095102's enrollment target sits among peer trials
311 15th of 45 higher than 31 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI